Zevra Therapeutics Inc

NASDAQ:ZVRAUnited States

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

Contact Information

Headquarters

1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION, FL, United States 34747

Phone

321-939-3416

Fax

319-665-2577

Executives

Independent Chairman of the Board

Tamara Favorito

President, Chief Executive Officer, Director

Neil Mcfarlane

Chief Financial Officer, Treasurer, Secretary

R. LaDuane Clifton

Chief People Officer

Alison Peters

Executive Vice President - Business Development, Chief Commercial Officer

Joshua Schafer